Exploring a mutation-based signature to predict the benefits of immune checkpoint inhibitors in oncogene-addicted subsets of non-small cell lung cancer: a retrospective study
The mutation-based signature established herein represents a robust biomarker for identifying patients with advanced NSCLCs who are most likely to benefit from ICB therapy, including those with targetable oncogene alterations.
Authors
- Zhilin Sui
- Songhua Cai (ORCID: https://orcid.org/0000-0003-3839-2030)
- Boying Xiao (ORCID: https://orcid.org/0000-0002-7969-0504)
- Wenyan Kang (ORCID: https://orcid.org/0000-0001-7527-7512)
- Jing Huang (ORCID: https://orcid.org/0000-0001-7593-0980)
- Chujian Huang
- Ran Jia (ORCID: https://orcid.org/0000-0001-9895-5734)
- Jinsong Lei (ORCID: https://orcid.org/0000-0002-3059-9005)
- Youjun Deng (ORCID: https://orcid.org/0000-0002-2904-6438)
Institutions
- Sun Yat-sen University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- National Cancer Center (US)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Respiratory Research
- Published
- 2025-11-22
- DOI
- https://doi.org/10.1186/s12931-025-03429-w
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00